The development of combination therapy involving camptothecins: A review of preclinical and early clinical studies

Cancer Treatment Reviews

Volumn 24, Issue 3, 1998, Pages 205-220

  De Jonge, M J A ^a   Sparreboom, A ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; IRINOTECAN; TOPOTECAN;

CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; HUMAN; HYPERBILIRUBINEMIA; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; THROMBOCYTOPENIA;

EID: 0031665530     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90050-0     Document Type: Article

References (153)

1. Hsiang YH & Liu LE. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48: 1722-1726.
2. Eng WK, Faucette L, Johnson RK, & Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol 1988; 34: 755-760.
3. Hsiang YH, & Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-5082.
4. Chen AY, & Liu LF. Mechanisms of resistance to topoisomerase inhibitors. Cancer Treat. Res. 1994; 73: 263-281.
5. Ohno R, Okada K, Masaoka T et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 1990; 8: 1907-1912.
6. Fukuoka M, Niitani H, Suzuki A. et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 1992; 10: 16-20.
7. Masuda N, Fukuoka M, Kusunoki Y. et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 1992; 10: 1225-1229.
8. Shimada Y, Yoshino M, Wakui A. et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. 1993; 11: 909-913.
9. Kambe M, Wakui A, Nakao I. et al. A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer. Proc. ASCO 1993; 12: 198 (abstract 584).
10. Wagener DJ Th, Verdonk HER, Dirix LY. et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann. Oncol. 1995; 6: 129-132.
11. Conti JA, Kemeny NE, Saltz LB. et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol. 1996; 14: 709-715.
12. Rothenberg ML, Eckardt JR, Kuhn JG. et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol. 1996; 14: 1128-1135.
13. Rougier P, Bugat R, Douillard JY. et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol. 1997; 15: 251-260.
14. Verschraegen CF, Levy T, Kudelka AP. et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J. Clin. Oncol. 1997; 15: 625-631.
15. Pitot HC, Wender DB, O'Connell MJ. et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J. Clin. Oncol. 1997; 15: 2910-2919.
16. Lynch ThJ Jr, Kalish L, Strauss G. et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J. Clin. Oncol. 1994; 12: 347-352.
17. Creemers GJ, Wanders J, Gamucci T. et al. Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group. Ann. Oncol. 1995; 6: 844-846.
18. Perez-Soler R, Fossella FV, Glisson BS. et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol 1996; 14: 503-513.
19. Kudelka AP, Tresukosol D, Edwards CL. et al Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol 1996; 14: 1552-1557.
20. Macdonald D, Cairncross G, Stewart D. et al. Phase II study of topotecan in patients with recurrent malignant glioma. Ann. Oncol. 1996; 7: 205-207.
21. Schiller JH, Kim K-M, Hutson P. et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 1996; 14: 2345-2352.
22. Creemers GJ, Gerrits CJH, Schellens JHM. et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J. Clin. Oncol. 1996; 14: 2540-2545.
23. Robert F, Wheeler RH, Moltrop DC, Greene P. & Chen, S. Phase II study of topotecan in advanced head and neck cancer: Identification of an active new agent. Proc. ASCO 1994; 13: 281 (abstract 905).
24. Perez-Soler R, Glisson BS, Lee JS. et al Treatment of patients with small-cell lung cancer refractory to etoposide and cis-platin with the topoisomerase I poison topotecan. J. Clin. Oncol. 1996; 14: 2785-2790.
25. Creemers GJ, Bolis G, Gore M. et al. Topotecan an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol. 1996; 14: 3056-3061.
26. Perez-Soler R, Khuri F, Pisters KM. et al. Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy. Proc. ASCO 1997; 16: 450a (abstract 1619).
27. Gordon A, Bookman M, Malmstrom H. et al. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: international topotecan study group trial. Proc. ASCO 1996; 15: 282 (abstract 763).
28. Vietti T, Crist W, Ruby E. et al. Topotecan window in patients with rhabdomyosarcoma (RMS): an IRSG study. Proc. ASCO 1997; 16: 510a (abstract 1837).
29. Ardizzoni A, Hansen H, Dombernowsky P. et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J. Clin. Oncol. 1997; 15: 2090-2096.
30. Swisher EM, Mutch DG, Rader JS, Elbendary A. & Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynaecol. Oncol. 1997; 66: 480-486.
31. Husain I, Mohler JL, Seigler HF. & Besterman JF. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human rumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 1994; 54: 539-546.
32. Giovanella BC, Stehlin JS, Wall ME. et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 24: 1046-1048.
33. Van der Zee AGJ, Hollema H, de Jong S. et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 1991; 51: 5915-5920.
34. Hirabayashi N, Kim R, Nishiyama M. et al. Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues. Proc. AACR 1992; 33: 436 (abstract 2603).
35. Masumoto N, Nakano S, Esaki T, Fujishima H, Tatsumoto T. & Niho Y. Inhibition of cis-diamminedichloroplatinum (U)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int. J. Cancer 1995; 62: 70-75.
36. Boothman DA, Trask DK. & Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-Lapachone, an activator of topoisomerase I. Cancer Res. 1989; 49: 605-612.
37. Rumbos H. & Grosovsky A. Regulation of topoisomerase I activity following DNA damage: evidence for a topoisomerase I complex. Proc. AACR 1997; 38:181 (abstract 1214).
38. Fukuda M, Nishio K, Kanzawa F. et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 1996; 56: 789-793.
39. Aoe K, Kiura K, Ueoka H. et al. Down-regulation of topoisomerase I induced by cisplatin. Proc. AACR 1997; 38: 15 (abstract 99).
40. Takiyama I, Terashima M, Ikeda K. et al. Remarkable synergistic interaction between camptothecin analogs and cisplatin against human esophageal cancer cell lines. Proc. AACR 1997; 38: 15 (abstract 101).
41. Ma J, Maliepaard M, Nooter K. et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother. Pharmacol. 1998; 41: 307-316.
42. Maliepaard M, van Klink Y, Floot BJG, Ruevekamp M. & Schellens JHM. Schedule-dependent cytotoxicity of topotecan or SN-38 and platinum (II) and (IV) compounds in vitro. In: Proc. 8th Conference on DNA Topoisomerase, 1997; abstract 92.
43. Keane T, McGuire W, Petros J, Sun C. & Graham S Jr CPT-11 cisplatin: an effective preclinical combination in the therapy of advanced human bladder cancer (TCC). Proc. ASCO 1995; 14: 491 (abstract 1605).
44. Kano, Y, Suzuki, K., Akutsu, M. et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer 1992; 50: 604-610.
45. Katz EJ, Vick JS, Kling KM, Andrews PA. & Howell SB. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur. J. Cancer 1990; 26: 724-727.
46. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T. & Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer 1992; 50: 760-766.
47. Kaufmann SH, Peereboom D, Buckwalter CA. et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J. Natl. Cancer Inst. 1996; 88: 734-741.
48. Chou T-C, Motzer RJ, Tong Y. & Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 1994; 86: 1517-1524.
49. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, & Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother. Pharmacol. 1998; 41: 385-390.
50. Rowinsky EK, Kaufmann SH, Baker SD. et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol. 1996; 14: 3074-3084.
51. Waud WR, Rubinstein LV, Kalyandrug S, Plowman J. & Alley MC. In vivo combination chemotherapy evaluations of topotecan with cisplatin and temozolomide. Proc. AACR 1996; 37: 292 (abstract 1988).
52. Bissery MC, Vrignaud P. & Lavelle F. In vivo evaluation of the irinotecan-oxaliplatin combination. Proc. ECCO 1997; 33: S177 (abstract 793).
53. Raymond E, Djelloul S, Buquet-Fagot C. et al. Oxaliplatin (LOHP) and cisplatin (CDDP) in combination with 5FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD694) and topoisomerase I (Topo-I) inhibitors (SN38, CPT-11), in human colonic, ovarian and breast cancers. Proc. AACR 1996; 37: 291 (abstract 1981).
54. Zehhari-Squalli N, Misset J-L, Cvitkovic E. & Goldwasser F. Cellular pharmacology of the combination of oxaliplatin and SN38. In: Proc. 8th Conference on DNA Topoisomerase, 1997, (abstract 102).
55. Goldwasser F, Valenti M, Torres R, Kohn KW. & Pommier Y. Potentiation of cisplatin cytotoxicity by 9-Aminocamptothecin. Clin. Cancer Res. 1996; 2: 687-693.
56. Pourquier P, Pilon AA, Kohlhagen G, Mazumder A, Sharma A. & Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. J. Biol. Chem. 1997; 272: 26441-26447.
57. Masuda N, Fukuoka M, Takada M. et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol. 1992; 10: 1775-1780.
58. Masuda N, Fukuoka M, Kudoh S. et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br. J. Cancer 1993; 68: 777-782.
59. Sugiyama T, Takeuchi S, Noda K, & Yakushiji M. CPT-11 Study Group on Gynecologic Malignancy. Phase I study of irinotecan (CPT-11) in combination with cisplatin (CDDP) on cervical carcinoma. Proc. ASCO 1994; 13: 268 (abstract 856).
60. Kobayashi K, Soma T, Shinbara A. et al. Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) by divided administration in patients with non-small cell lung cancer (NSCLC). Proc. ASCO 1996; 15: 388 (abstract 1169).
61. Shirao K, Shimada Y, Kondo H. et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J. Clin. Oncol. 1997; 15:921-927.
62. Ueoka H, Tabata M, Shibayama T. et al. A phase I study of irinotecan (CPT-11) and cisplatin (CDDP) in advanced lung cancer (ED-SCLC and IIIB/IV-NSCLC). Proc. ASCO 1996; 15: 385 (abstract 1154).
63. Mori K, Ohnishi T, Yokoyama K. & Tominaga K. A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 1997; 39: 327-332.
64. Saltz L, Kanowitz J, Kelsen D. et al. Phase I study of weekly cisplatin (CDDP) plus irinotecan (CPT-11) in patients (PTS) with advanced solid tumors. Proc. ASCO 1996; 15: 484 (abstract 1540).
65. Masuda N, Fukuoka M, Kudoh S. et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J. Clin. Oncol 1994; 12: 90-96.
66. Mori K, Hirose T, Machida S, Yokoyama K. & Tominaga K. A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur. J. Cancer 1997; 33: 503-505.
67. Mick R, Gupta E, Vokes EE, & Retain MJ. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliairy index and intestinal toxicity. J. Clin. Oncol. 1996; 14: 2012-2019.
68. Sumiyoshi H, Fujiwara Y, Ohoshi N, Egusa Y, Yamaoka N, & Yamakido M. Clinical pharmacological evaluation of CPT-11 and cisplatin (CDDP) in patients with small cell lung cancer (SCLC). Proc. ASCO 1995; 14: 457 (abstract 1470).
69. Rothenberg ML, Kuhn JG, Burris HA III. et al. Phase I and pharmacokinetic trial of weekly CPT-II. J. Clin. Oncol. 1993; 11: 2194-2204.
70. Negoro S, Fukuoka M, Masuda N. et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 1991; 83: 1164-1168.
71. De Forni M, Bugat R, Chabot GG. et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 1994; 54: 4347-4354.
72. Chabot GG, Abigerges D, Catimel G. et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol. 1995; 6: 141-151.
73. Shinkai T, Arioka H, Eguchi K. et al. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-campothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. 1994; Cancer Res. 54: 2636-2642.
74. Sugiura S, Saka H, Ando M. et al. Phase I dose escalation study of carboplatin (CBDCA) and irinotecan (CPT-11). Proc. ASCO 1997; 16: 252a (abstract 890).
75. Okamoto H, Nagatomo A, Kunitoh H, & Watanabe K. A combination phase-I-II study of carboplatin/irinotecan plus G-CSF with the Calvert equation in patients with advanced non-small cell lung cancer (NSCLC). Proc. ASCO 1995; 14: 373 (abstract 1150).
76. Cvitkovic E, Wasserman E, Goldwasser F. et al. Oxaliplatin (L-OHP)/CPT-11 combination: phase I study, preliminary results of an active combination in colorectal cancer (CRC). In: Proc. 8th Conference on DNA Topoisomerase, 1997, abstract 96.
77. Lokiec F, Wasserman E, Cvitkovic E. et al. Final results of the pharmacokinetic study of both CPT-11 (C) and LOHP (L) in combination during a phase I trial in gastrointestinal cancer patients. Proc. ASCO 1998; 17: 202a (abstract 778).
78. Raymond E, Burris HA, Rowinsky EK. et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carinoma. Ann. Oncol. 1997; 8: 1003-1008.
79. Miller AA, Hargis BJ, Lilenbaum RC, Fields SZ, Fields SZ, Rosner GL, & Schilsky RL. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J. Clin. Oncol. 1994; 12: 2743-2750.
80. Saltz L, Kanowitz J, Schwartz G. et al. Phase I trial of cisplatin (DDP) plus topotecan (T) on a daily ×5 schedule in patients with advanced solid tumors. Proc. ASCO 1995; 14: 475 (abstract 1541).
81. Lilenbaum RC, Miller AA, Batist G. et al. Phase I study of continuous IV infusion topotecan (TT) in combination with cisplatin (C) in patients with advanced cancer (CALGB 9462). Proc. ASCO 1996; 15: 485 (abstract 1543).
82. Miller A, Lilenbaum RC, Lynch Th J. et al. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J. Clin. Oncol. 1996; 14: 1964-1965.
83. Heideman R, Kuttesch J, Stewart C. et al. A phase I trial of a fixed systemic exposure (AUC) of carboplatin (CARBO) with continuous infusion (CI) topotecan (TOPO) in paediatric solid tumors. Proc. ASCO 1995; 14: 447 (abstract 1430).
84. Miller CB, O'Reilly S, Sartorius S. et al. A phase I and pharmacologic study of a combination of cyclophosphamide (CY) and topotecan (TOPO) in patients (pts) with refractory leukemia. Proc. ASCO 1997; 16: 203a (abstract 712).
85. Saylors RL III, Stewart CF, Zamboni WC. et al Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J. Clin. Oncol. 1998; 16: 945-952.
86. Murren JR, Andersen S, Fedele J. et al. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J. Clin. Oncol. 1997. 15: 148-157.
87. Shimizu Y, Umezawa S, Hasumi K, Yamauchi K, & Silverberg SG. Efficacy of a combination of irinotecan (CPT-11) with mitomycin-C (MMC) for clear cell carcinoma of the ovary (OCCA) which is intrinsically platinum resistant. Proc. ECCO 1997; 33: S119 (abstract 530).
88. Ferguson PJ, Fisher MH, Stephenson J, Li D, Zhou B. & Cheng Y. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 1988; 48: 5956-5964.
89. Matsuo K, Kohno K, Takano H, Sato S, Kiue A. & Kuwano M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res. 1990; 50: 5819-5824.
90. Lefevre D, Riou J-F, Ahomadegbe JC, Zhou D, Benard J. & Riou G. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and the acidic glutathione S transferase. Biochem. Pharmacol. 1991; 41: 1967-1979.
91. Gupta RS, Gupta R, Eng B. et al. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 1988; 48: 6404-6410.
92. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF. & Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant tumor cell lines. Cancer Res. 1990; 50: 7962-7965.
93. Kaufmann S. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in human leukemia cell line. Cancer Res 1991; 51: 1129-1136.
94. Janss AJ, Cnaan A, Spilsky A, Levow C, Yao Y. & Phillips PC. Synergistic cytotoxic effects of camptothecin and topotecan with alkylating agents are drug-specific and dose-dependent in human brain tumor cell lines. Proc. AACR 1996; 37: 294 (abstract 1996).
95. Bertrand R, O'Connor PM, Kerrigan D. & Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer 1992; 28A: 743-748.
96. Whitacre CM, Zborowska E, Gordon NH, Mackay W. & Berger NA. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res. 1997; 57: 1425-1428.
97. Ciesielski MJ, & Fenstermaker RA. Combination therapy with 9-aminocamptothecin (9-AC) and etoposide (VP-6) in human glioblastoma. Proc. AACR 1996; 37: 427 (abstract 2918).
98. Anzai H, Frost P, Abbruzese JL. Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II. Proc. AACR 1992; 33: 431 (abstract 2573).
99. Houghton JA, Cheshire PJ, Hallman JD II. et al. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdo-myosarcoma. Clin. Cancer Res. 1996; 2: 107-118.
100. Eder JP, Ikebe M, Wong E, Rizvi N, Chan VT-W. & Teicher BA. CPT-11/topoisomerase II (topo II) inhibitor combination therapy: molecular pharmacology and therapeutic response. Proc. AACR 1996; 37: 430 (abstract 2937).
101. Kozelsky TK. & Bonner JA. Sequence dependent interaction of etoposide and topotecan. Proc. AACR 1995; 36: 293 (abstract 1744).
102. Bonner JA. & Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother. Pharmacol. 1996; 39: 109-112.
103. Jensen PB, Sorensen M, Christensen LJ. & Sehested M. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br. J. Cancer 1997; 75: 869-877.
104. Whitacre CM, Berger SJ, Belfi CA, Gosky DM, Sbrocco LM. & Berger NA. Effect of topotecan on topoisomerase II expression in human cell lines. Proc. AACR 1996; 37: 434 (abstract 2965).
105. Eckardt JR, Burris HA, Von Hoff DD. et al. Measurement of tumor topoisomerase I and II levels during the sequential administration of topotecan and etoposide. Proc. ASCO 1994; 13: 141 (abstract 358).
106. Vasey PA, Kaye SB. Combined inhibition of topoisomerases I and II - is this a worthwhile/feasible strategy? Br. J. Cancer 1997. 76: 1395-1397.
107. Ando M, Eguchi K, Shinkai T. et al. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-lung cancer. Br. J. Cancer 1997; 76: 1494-1499.
108. Karato A, Sasaki Y, Shinkai T. et al. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J. Clin. Oncol. 1993; 11: 2030-2035.
109. Masuda N, Fukuoka M, Kudoh S. et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J. Clin. Oncol. 1994; 12: 1833-1841.
110. Negoro S, Fukuoka M, Masuda N. et al. Phase I study of irinotecan (CPT-11) and etoposide (E) with G-CSF in advanced lung cancer. Proc. ASCO 1993; 12: 133 (abstract 331).
111. Crump M, Lipton J, Hedley D. et al. A phase I trial of sequential topotecan and etoposide in adult acute myeloid leukemia (AML). Proc. ASCO 1996; 15: (abstract 1050).
112. Cooper BW, Lazarus HM, Creger R. et al. A phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory/relapsed acute leukemia (RAL). Proc. ASCO 1996; 15: 486 (abstract 1549).
113. Eckardt JR, Burris HA, Rodriguez GA. et al. A phase I study of the topoisomerase I and II inhibitors topotecan (T) and etoposide (E). Proc. ASCO 1993; 12: 137 (abstract 349).
114. Herben VMM, ten Bokkel Huinink WW, Dubbelman AC. et al. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br. J. Cancer 1997; 76: 1500-1508.
115. Tolcher AW, O'Shaugnessy JA, Weiss RB. et al. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin. Cancer Res. 1997; 3: 755-760.
116. Karato A, Sasaki Y, Shiraishi J. et al. Pharmacokinetic study in the dose escalation study of CPT-11 and VP-16. Proc. AACR 1993; 34: 390 (abstract 2325).
117. Saotome T, Takagi T, Kumagai K, Takeshita A, Goto S, Sakai C. Combination chemotherapy with irinotecan and adriamycin for refractory or relapsed malignant lymphoma (ML): a pilot study. Ann. Oncol 1996; 7(Suppl. 5): 113 (abstract 540P).
118. Guichard S, Cussac D, Mennebelle I, Bugat R, Canai P. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int. J. Cancer 1997; 73: 729-734.
119. Grivicich I, Mans DRA, da Rocha AB, Dalla Costa HS. & Schwartsmann G. The cytotoxicity of the irinotecan (CPT-11)-5-flourouracil (5-FU) combination in human colon carcinoma cell lines is related to the sequence-dependent introduction of DNA lesions. Proc. AACR 1997; 38: 318 (abstract 2133).
120. Mans DRA, Brondani da Rocha A, Gricivich I. & Sanvitto Della Costa H, Schwartsmann G. The cytotoxicity of the irinotecan (CPT-11)-5-fluorouracil (5-FU) combination in human colon carcinoma cell lines is sequence-dependent. Ann Oncol 1996; 7 (Suppl. 5): 9 (abstract 36P).
121. Harstrick A, Schleucher N, Vanhoefer U. et al. Cytotoxic interactions of SN38, the active metabolite of irinotecan, and 5-FU or tomudex in 5-FU sensitive and 5-FU resistant colorectal carcinoma cell lines. Ann Oncol 1996; 7 (Suppl. 5): 5 (abstract 13P).
122. Funakoshi S, Aiba K, Shibata H. et al. Enhanced antitumor activity of SN-38, an active metabolite of CPT-11, and 5-fluorouracil combination for human colorectal cancer cell lines. Proc. ASCO 1993; 12: 193 (abstract 563).
123. Taron M, Abad A, Mate JL. et al. Schedule dependency of the synergism between combination of topotecan, 5-fluoruracil and tomudex in HT29 and LOVO human adeno-carcinoma cell lines. Proc. ASCO 1996; 15: 500 (abstract 1601).
124. Guichard S, Hennebelle I, Canal P. Antitumoral activity and evaluation of cellular targets during repetitive courses of CPT-11 and 5FU combination in HT-29 nude mice xenografts. In: Proc. 8th Conference on DNA Topoisomerase, 1997. abstract 103.
125. Aschele, C., Sobrero, A., Baldo, C., Ardizzoni, A., Bornmann, W. G, Bertino J. R. (1996) In vitro synergism between SN-38 and tomudex (TX): importance of scheduling and dose ratio. Ann Oncol. 1996; (Suppl. 5): 129 (abstraact 621P).
126. Saltz LB, Kanowitz J, Kemeny NE. et al. Phase I clinical and pharmacokinetic study of irinotecan, flourouracil, and leucovorin in patients with advanced solid tumors. J. Clin. Oncol. 1996; 14: 2959-2967.
127. Sasaki Y, Ohtsu A, Shimada Y, Ono K. & Saijo N. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J. Natl. Cancer Inst. 1994; 86: 1096-1098.
128. Carcas AJ, Frias J, Hernanz A. et al. Pharmacokinetics of irinotecan (CPT-11) and 5-flourouracil (5-FU) in a dose finding study in adult patients with solid tumours. Proc. ECCO 1997; 33: S248 (abstract 1121).
129. Yamao T, Shimada Y, Shirao K. et al. Phase I study of CPT-11 combined with sequential 5FU in metastatic colorectal cancer (CRC). Proc. ASCO 1996; 15: 481 (abstract 1527).
130. Benhammouda A, Bastian G, Rixe O. et al. A phase I and pharmacokinetic (PK) study of CPT-11 (C) and 5-FU (F) combination. Proc. ASCO 1997; 16: 202a (abstract 710).
131. Fonseca R, Goldberg RM, Erlichman C, Sloan JA, Kaufmann SH. & Miller LL. Phase I study of the combination of CPT-11/5-FU and leucovorin (LV). Proc. ASCO 1998; 17: 203a (abstract 781).
132. Shimida Y, Sasaki Y, Sugano K. et al. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc ASCO 1993; 12: 196 (abstract 575).
133. Sastre J, Paz-Ares L, Diaz-Rubio E. et al. Phase I dose finding study of irinotecan (CPT-11) over a short i.v. infusion combined with a fixed dose of 5-fluorouracil (5-FU) over a protracted infusion in patients (pts) with advanced solid tumors. Proc. ASCO 1998; 17: 201a (abstract 775).
134. Vanhoefer U, Harstrick A, Achterrath W. et al. Phase I study of a weekly schedule of irinotecan (CPT-11), high dose folinic acid (FA) and 5-fluorouracil (5-FU) as first line chemotherapy (CT) in metastatic colorectal cancer: final results. Proc. ASCO 1998; 17: 202a (abstract 779).
135. Ducreaux, M, Rougier Ph, Ychou M. et al. Phase I/II study of escalating dose of CPT-11 in combination with LV5FU2 ("De Gramont" regimen) every two weeks in the treatment of colorectal cancer (CRC) after 5-FU failure. Proc. ASCO 1997; 16: 234a (abstract 823).
136. st line chemotherapy (CT) of metastatic colorectal cancer (CRC): preliminary results. Proc. ECCO 1997; 33: S169 (abstract 758).
137. Rothenberg ML, Pazdur R, Rowinsky EK. et al. A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer (CRC). Proc. ASCO 1997; 16: 266a (abstract 944).
138. Cunningham D, Ross P, Webb A. et al. Phase I dose finding study of irinotecan hydrochloride trihydrate (CPT11) with tomudex (TX) in patients with 5-FU refractory colorectal cancer. Proc. ECCO 1997; 33: S172 (abstract 770).
139. Seiter K, Feldman EJ, Halicka HD. et al. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J. Clin. Oncol. 1997; 15: 44-51.
140. Bissery MC, Vrignaud P. & Lavelle F. In vivo evaluation of the docetaxel-irinotecan combination. Proc. AACR 1996; 37: 378 (abstract 2578).
141. Lilenbaum RC, Ratain MJ, Miller AA. et al Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B study. J. Clin. Oncol. 1995; 13: 2230-2237.
142. O'Reilly S, Fleming GF, Baker SD. et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J. Clin. Oncol. 1997; 15: 177-186.
143. Hochster H, Chachoua A, Sorich J. et al. Phase I study of paclitaxel (P) combined with 14-day topotecan (T) continuous IV (CTV) infusion in previously treated and untreated patients (pts). Proc. ASCO 1997; 16: 238a (abstract 839).
144. Couteau C, Lokiec F, Vernillet L. et al. Phase I dose-finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors. Proc. ASCO 1997; 16: 202a (abstract 709).
145. Kudoh S, Negoro S, Masuda N. et al. Phase I/II study of docetaxel (DOC) and irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC). Proc. ASCO 1998; 17: 491a (abstract 1891).
146. Mori K, Hirose T, Tominaga K. Phase II study irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Proc. ASCO 1997; 16: 476a (abstract 1714).
147. DeVore R, Crawford J, Dimery I. et al. Phase II trial of irinotecan (CPT-11) plus cisplatin (CDDP) in advanced NSCLC. Proc. ASCO 1997; 16: 466a (abstract 1674).
148. Oshita F, Noda K, Nishiwaki Y. et al. Phase II study of irinotecan and etoposide in patients with metastatic non-small lung cancer. J. Clin. Oncol. 1997; 15: 304-309.
149. Wiesenfeld M, Marks R, Grill J. et al. A randomized phase II study of topotecan (TOPA) and cisplatin (CDDP) with filgrastim (G-CSF) versus topotecan and paclitaxel (Taxol®) with filgrastim in patients with advanced non-small cell lung cancer. Proc. ASCO 1997; 16: 466a (abstract 1755).
150. Kudoh S, Fujiwara Y, Takada Y. et al. Phase II study of irinotecan combined with cisplatin in patients with pre-viously untreated small-cell lung cancer. J. Clin. Oncol. 1998; 16: 1068-1074.
151. Boku N, Ohtsu A, Shimada Y. et al. Phase II study of a combination of CDDP and CPT-11 in metastatic gastric cancer: CPT-11 study group for gastric cancer. Proc. ASCO 1997; 16: 264a (abstract 936).
152. Sugiyama T, Nishida T, Ushijima K, Kumagai S, Yskushiji M. Irinotecan hydrochloride (CPT-11) combined with cisplatin (CDDP) in patients with relapsed or metastatic ovarian cancer. Proc. ASCO 1996; 15: 291 (abstract 796).
153. Sugiyama T, Noda K, Yakushiji M. Multicentric phase II trial of irinotecan (CPT-11) and cisplatin as first-line chemotherapy in recurrent or advanced cervical cancer: Japan CPT-11 study group trial. Proc. ASCO 1998; 17: 352 (abstract 1360).